These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32577695)

  • 1. Sex differences in immune responses to SARS-CoV-2 that underlie disease outcomes.
    Takahashi T; Wong P; Ellingson MK; Lucas C; Klein J; Israelow B; Silva J; Oh JE; Mao T; Tokuyama M; Lu P; Venkataraman A; Park A; Liu F; Meir A; Sun J; Wang EY; Wyllie AL; Vogels CBF; Earnest R; Lapidus S; Ott IM; Moore AJ; Casanovas-Massana A; Cruz CD; Fournier JB; Odio CD; Farhadian S; Grubaugh ND; Schulz WL; Ko AI; Ring AM; Omer SB; Iwasaki A;
    medRxiv; 2020 Jun; ():. PubMed ID: 32577695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex differences in immune responses that underlie COVID-19 disease outcomes.
    Takahashi T; Ellingson MK; Wong P; Israelow B; Lucas C; Klein J; Silva J; Mao T; Oh JE; Tokuyama M; Lu P; Venkataraman A; Park A; Liu F; Meir A; Sun J; Wang EY; Casanovas-Massana A; Wyllie AL; Vogels CBF; Earnest R; Lapidus S; Ott IM; Moore AJ; ; Shaw A; Fournier JB; Odio CD; Farhadian S; Dela Cruz C; Grubaugh ND; Schulz WL; Ring AM; Ko AI; Omer SB; Iwasaki A
    Nature; 2020 Dec; 588(7837):315-320. PubMed ID: 32846427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Divergent androgenic modulation of SARS-CoV-2 infection cooperates with dysregulated immune response to dictate worse COVID-19 outcomes in men.
    Duarte-Silva M; Oliveira CNS; Fuzo C; Silva-Neto PV; Toro DM; Pimentel VE; Pérez MM; Fraga-Silva TFC; Carvalho JCS; Neto FMS; Júnior RBM; Arruda E; Vilar FC; Degiovani AM; Ostini FM; Feitosa MR; Parra RS; Gaspar GG; Rocha JJR; Feres O; Fernandes APM; Maruyama SR; Russo EMS; Bonato VLD; Santos IKFM; Sorgi CA; Dias-Baruffi M; Faccioli LH; Cardoso CRB;
    Brain Behav Immun; 2023 Nov; 114():275-286. PubMed ID: 37648004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China.
    Wu F; Liu M; Wang A; Lu L; Wang Q; Gu C; Chen J; Wu Y; Xia S; Ling Y; Zhang Y; Xun J; Zhang R; Xie Y; Jiang S; Zhu T; Lu H; Wen Y; Huang J
    JAMA Intern Med; 2020 Oct; 180(10):1356-1362. PubMed ID: 32808970
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Viurcos-Sanabria R; Manjarrez-Reyna AN; Solleiro-Villavicencio H; Rizo-Téllez SA; Méndez-García LA; Viurcos-Sanabria V; González-Sanabria J; Arroyo-Valerio A; Carrillo-Ruíz JD; González-Chávez A; León-Pedroza JI; Flores-Mejía R; Rodríguez-Cortés O; Escobedo G
    Front Immunol; 2022; 13():897995. PubMed ID: 35860236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study.
    Yin SW; Zhou Z; Wang JL; Deng YF; Jing H; Qiu Y
    Virol J; 2021 Jun; 18(1):126. PubMed ID: 34118952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.
    Guo L; Wang G; Wang Y; Zhang Q; Ren L; Gu X; Huang T; Zhong J; Wang Y; Wang X; Huang L; Xu L; Wang C; Chen L; Xiao X; Peng Y; Knight JC; Dong T; Cao B; Wang J
    Lancet Microbe; 2022 May; 3(5):e348-e356. PubMed ID: 35345417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?
    Gemmati D; Bramanti B; Serino ML; Secchiero P; Zauli G; Tisato V
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32423094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection.
    Conti P; Younes A
    J Biol Regul Homeost Agents; 2020 March-April,; 34(2):339-343. PubMed ID: 32253888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and immunological features associated to the development of a sustained immune humoral response in COVID-19 patients: Results from a cohort study.
    Torres-Ruiz J; Lomelín-Gascón J; Vargas-Castro AS; Lira-Luna J; Pérez-Fragoso A; Tapia-Conyer R; Nuñez-Aguirre M; Alcalá-Carmona B; Absalón-Aguilar A; Maravillas-Montero JL; Mejía-Domínguez NR; Núñez-Álvarez C; Rull-Gabayet M; Llorente L; Romero-Ramírez S; Sosa-Hernández VA; Cervantes-Díaz R; Juárez-Vega G; Meza-Sánchez DE; Martínez-Juárez LA; Morales-Juárez L; López-López LN; Negrete-Trujillo JA; Falcón-Lezama JA; Valdez-Vázquez RR; Gallardo-Rincón H; Gómez-Martín D
    Front Immunol; 2022; 13():943563. PubMed ID: 36045688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interplay of Antibody and Cytokine Production Reveals CXCL13 as a Potential Novel Biomarker of Lethal SARS-CoV-2 Infection.
    Horspool AM; Kieffer T; Russ BP; DeJong MA; Wolf MA; Karakiozis JM; Hickey BJ; Fagone P; Tacker DH; Bevere JR; Martinez I; Barbier M; Perrotta PL; Damron FH
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33472985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of platelet-and endothelial-associated biomarkers of disease activity in people hospitalized with Covid-19 with and without HIV co-infection.
    van der Mescht MA; Steel HC; de Beer Z; Abdullah F; Ueckermann V; Anderson R; Rossouw TM
    Front Immunol; 2023; 14():1235914. PubMed ID: 37646024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuro-axonal injury in COVID-19: the role of systemic inflammation and SARS-CoV-2 specific immune response.
    Hirzel C; Grandgirard D; Surial B; Wider MF; Leppert D; Kuhle J; Walti LN; Schefold JC; Spinetti T; Suter-Riniker F; Dijkman R; Leib SL
    Ther Adv Neurol Disord; 2022; 15():17562864221080528. PubMed ID: 35299779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations.
    Titova E; Kan VW; Lozy T; Ip A; Shier K; Prakash VP; Starolis M; Ansari S; Goldgirsh K; Kim S; Pelliccia MC; Mccutchen A; Megalla M; Gunning TS; Kaufman HW; Meyer WA; Perlin DS
    Microbiol Spectr; 2024 Mar; 12(3):e0205023. PubMed ID: 38353557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients.
    Lafon E; Diem G; Witting C; Zaderer V; Bellmann-Weiler RM; Reindl M; Bauer A; Griesmacher A; Fux V; Hoermann G; Miller C; Zabernigg A; Wöll E; Wilflingseder D; Lass-Flörl C; Posch W
    Front Immunol; 2021; 12():684014. PubMed ID: 34194438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients.
    Pierce CA; Preston-Hurlburt P; Dai Y; Aschner CB; Cheshenko N; Galen B; Garforth SJ; Herrera NG; Jangra RK; Morano NC; Orner E; Sy S; Chandran K; Dziura J; Almo SC; Ring A; Keller MJ; Herold KC; Herold BC
    Sci Transl Med; 2020 Oct; 12(564):. PubMed ID: 32958614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct systemic immune networks define severe
    Pignataro-Oshiro F; Figueiredo AB; Galdino NAL; Morais KLP; Dutra WO; Silva BGM; Feriani D; Abrantes FA; Silva ILAFE; Filho JS; Framil JVS; Cesca MG; Riechelmann RSP; Batista MV; Gollob KJ
    Front Immunol; 2022; 13():1052104. PubMed ID: 36700209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study.
    Hu Z; van der Ploeg K; Chakraborty S; Arunachalam PS; Mori DAM; Jacobson KB; Bonilla H; Parsonnet J; Andrews JR; Holubar M; Subramanian A; Khosla C; Maldonado Y; Hedlin H; de la Parte L; Press K; Ty M; Tan GS; Blish C; Takahashi S; Rodriguez-Barraquer I; Greenhouse B; Butte AJ; Singh U; Pulendran B; Wang TT; Jagannathan P
    Elife; 2022 Oct; 11():. PubMed ID: 36239699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.